THE 30-SECOND OVERVIEW
Ipamorelin dosage research quick start
Ipamorelin is discussed as though it has a settled protocol behind it. It does not. It reached clinical development, the programme stopped, and most of what circulates as an ipamorelin dose is convention rather than a published figure.
Check the formulation
Ipamorelin 8 mg vial. Other formats and blends may have different strengths.
Amount ≠ schedule
Concentration arithmetic does not determine dosing frequency or a safe human daily amount.
LABORATORY CONCENTRATION MATH
Ipamorelin dosage calculator
Calculate the amount in a laboratory sample of the 8 mg Ipamorelin vial. Enter the final solution volume, not the container capacity.
Enter positive volumes; the sample cannot exceed the final solution volume.
Illustrative arithmetic only. These inputs are not recommended preparation volumes or doses. This calculator does not recommend a route or schedule for human use.
What ipamorelin is
Ipamorelin is a synthetic pentapeptide and a growth hormone secretagogue. It binds the ghrelin receptor, which is the same receptor the growth hormone releasing peptides act on, and prompts the pituitary to release growth hormone. The same receptor is the target of MK-677, an orally active small-molecule ghrelin mimetic that is not a peptide at all; it is stocked as an oral liquid and as tablets.
The reason it drew interest is selectivity. Earlier secretagogues in the same family also raised cortisol, prolactin, and adrenocorticotropic hormone at doses that released growth hormone. Raun and colleagues, publishing in the European Journal of Endocrinology in 1998, characterised ipamorelin as releasing growth hormone with far less effect on those other hormones in rats and swine. That selectivity claim is the whole basis of ipamorelin's reputation, and it comes from preclinical work.
Note the mechanism it does not use. Ipamorelin acts on the ghrelin receptor, while tesamorelin is a GHRH analogue acting on a different receptor. The two are often grouped as growth hormone compounds and then compared as if interchangeable, which they are not.
What happened in clinical development
Ipamorelin was taken into human trials, but not for the reasons it is discussed now. The clinical programme investigated it for postoperative ileus, the slowing of gut motility after abdominal surgery, on the basis that ghrelin receptor agonism affects gastric emptying.
That programme did publish a dose. The phase 2 trial infused 0.03mg/kg ipamorelin intravenously twice daily, from the day after bowel resection for up to seven days (Beck et al., 2014). It was well tolerated at that dose, and it showed no significant benefit over placebo on the motility endpoints it was designed around.
The programme was then discontinued. Development stopping is not the same as a compound failing on safety, and the public record does not support a strong claim either way about why. What it does mean is that ipamorelin has no approved indication, no label, and therefore no established dosing reference of the kind tesamorelin has through its approval history.
So the honest position is this: ipamorelin has human exposure data from a discontinued programme aimed at a different question, and no published protocol for the uses it is now associated with.
Where the circulating figures come from
Search for an ipamorelin dose and you will find fairly consistent numbers. That consistency is worth examining rather than trusting, because consistency across sources can mean agreement with evidence or agreement with each other.
The commonly repeated figures trace back to vendor convention and community practice rather than to a trial. They are not absurd, in that they sit in a plausible range for a peptide of this class, but nothing in the published literature establishes them.
Where published dosing does exist, it is preclinical and expressed per kilogram of body weight. In the Raun work, ipamorelin released growth hormone in conscious swine with an intravenous ED50 of 2.3nmol/kg, which is a pharmacology potency figure, not a protocol. Converting animal per-kilogram figures to a human quantity requires allometric scaling, which is an estimate built on assumptions about metabolism between species, not a conversion factor.
Timing and the pulsatile problem
One thing the mechanism does tell you clearly. Growth hormone is released in pulses, concentrated in the hours after sleep onset, and secretagogues amplify the body's own pulses rather than supplying hormone directly.
That is why protocols in this class are built around timing rather than a single daily quantity, and why studies of secretagogues pay attention to when administration happens relative to sleep and to food. Ghrelin receptor activity interacts with feeding state, so a protocol that ignores timing is discarding a variable the mechanism says matters.
Reconstitution and handling
Ipamorelin is supplied lyophilised and needs reconstitution. It is a short peptide with no unusual instability, so ordinary handling applies.
Add diluent slowly against the vial wall rather than onto the powder, swirl instead of shaking, and keep the reconstituted solution cold and dark. Treat solution life as much shorter than powder life.
Concentration is set by diluent volume. The same 8mg reconstituted in 1mL and in 2mL gives solutions differing twofold, so any volume carried across from a differently prepared vial is wrong by that ratio. Recalculate per vial, or use our peptide calculator. Purity and identity for each lot are in our lab results.
What the research does not establish
The selectivity finding is preclinical. Ipamorelin releasing growth hormone with minimal cortisol and prolactin response was shown in animals, and the extent to which that holds across human dose ranges is not established by the published record.
The clinical data that exists studied gut motility, not the endpoints ipamorelin is now discussed for. Borrowing exposure data from one question to support claims about another is an assumption.
And there is no long-duration human data. The trials were short and aimed elsewhere, so questions about extended administration are open.
The takeaway
Ipamorelin has a clear mechanism, a preclinical selectivity finding worth taking seriously, human exposure from a discontinued programme about postoperative ileus, and no published protocol for anything else. Anyone citing a specific ipamorelin dose is citing convention. That is worth knowing before designing around it. Our ipamorelin for sale listing covers the 8mg vial and the nasal spray.
Researchers comparing it with GHRH analogues should note the receptors differ, and that blends pairing the two, such as CJC-1295 with ipamorelin, are combining two mechanisms rather than doubling one.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Raun, K., Hansen, B. S., Johansen, N. L., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.
2. Beck, D. E., Sweeney, W. B., McCarter, M. D., et al. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527-1534.
